We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Candel Therapeutics Inc | NASDAQ:CADL | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.01 | 0.14% | 7.13 | 7.13 | 7.30 | 7.54 | 6.76 | 7.00 | 811,812 | 01:00:00 |
From Dec 2023 to Jun 2024
By Dean Seal
Shares of Candel Therapeutics surged after U.S. federal regulators granted fast-track designation to its treatment for pancreatic ductal adenocarcinoma.
The stock was up 58% at $1.37 in premarket trading. Shares had fallen 51% year-to-date when the market closed Monday.
The clinical-stage biopharmaceutical company said Tuesday that the U.S. Food and Drug Administration granted the designation for CAN-2409, its lead investigational adenovirus asset, plus valacyclovir as a treatment to improve overall survival in patients with pancreatic ductal adenocarcinoma.
The FDA's fast-track designation facilitates development and expedites the review of drugs that treat serious or life-threatening conditions and fill unmet medical needs.
Write to Dean Seal at dean.seal@wsj.com
(END) Dow Jones Newswires
December 12, 2023 08:43 ET (13:43 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Candel Therapeutics Chart |
1 Month Candel Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
